New ELN Recommendations

2017 ELN Guidelines: Overview

2016 Updated WHO Classification of AML

Molecular Landscape of AML

Molecular Classification of AML: Implications for Diagnosis

Diagnostic Workup of AML: Practical Considerations

Risk Stratification and Treatment Selection

Indications for Allogeneic Transplantation

Targeted Therapies for AML: Targeting FLT3

Targeted Therapies for AML: Targeting IDH2

Measurable/Minimal Residual Disease

Using MRD During Treatment to Assess Early Response

Using MRD After Treatment to Detect Early Relapse: Example From APL

Using MRD After Treatment to Detect Early Relapse: Example From CBF-AML

Prognostic Significance of FLT3-ITD Mutation vs MRD Status

Using MRD Status to Guide Treatment Selection

Prognostic Significance of Age vs Comorbidities/Performance Status

Selecting a Non-Intensive Treatment Approach

Assessing Response to Hypomethylating Agents

Azacitidine in Older Patients With AML 30+: AZA-AML-001 Phase 3 Trial

Outcomes With Azacitidine in Patients Who Do Not Achieve CR: AZA-AML-001

Managing Toxicities Associated With Hypomethylating Agents

Decitabine in Older Patients With AML: DACO-016 Phase 3 Trial

Outcomes With Decitabine in Patients With Baseline Hyperleukocytosis: DACO-016

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)